UMB Bank n.a. Purchases 107,976 Shares of Bristol-Myers Squibb (NYSE:BMY)

UMB Bank n.a. boosted its stake in shares of Bristol-Myers Squibb (NYSE:BMY - Free Report) by 52.6% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 313,433 shares of the biopharmaceutical company's stock after buying an additional 107,976 shares during the period. UMB Bank n.a.'s holdings in Bristol-Myers Squibb were worth $19,116,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of BMY. Pinney & Scofield Inc. acquired a new position in shares of Bristol-Myers Squibb in the 4th quarter valued at about $25,000. Park Square Financial Group LLC acquired a new position in shares of Bristol-Myers Squibb in the fourth quarter worth $26,000. Global Wealth Strategies & Associates boosted its position in Bristol-Myers Squibb by 137.5% during the first quarter. Global Wealth Strategies & Associates now owns 475 shares of the biopharmaceutical company's stock valued at $29,000 after purchasing an additional 275 shares during the last quarter. Transce3nd LLC purchased a new position in Bristol-Myers Squibb in the fourth quarter valued at about $28,000. Finally, Fairway Wealth LLC acquired a new position in Bristol-Myers Squibb in the 4th quarter worth about $28,000. 76.41% of the stock is owned by hedge funds and other institutional investors.

Bristol-Myers Squibb Price Performance

Shares of Bristol-Myers Squibb stock traded up $0.60 during trading on Monday, reaching $49.01. The company's stock had a trading volume of 9,861,388 shares, compared to its average volume of 13,044,821. The stock has a 50-day moving average price of $49.34 and a two-hundred day moving average price of $55.02. The stock has a market capitalization of $99.74 billion, a P/E ratio of -11.09, a price-to-earnings-growth ratio of 2.07 and a beta of 0.38. The company has a current ratio of 1.25, a quick ratio of 1.15 and a debt-to-equity ratio of 2.90. Bristol-Myers Squibb has a one year low of $39.35 and a one year high of $63.33.

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last announced its earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.80 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.50 by $0.30. The company had revenue of $11.20 billion for the quarter, compared to analyst estimates of $10.77 billion. Bristol-Myers Squibb had a negative net margin of 18.53% and a positive return on equity of 13.93%. Bristol-Myers Squibb's quarterly revenue was down 5.6% on a year-over-year basis. During the same period in the prior year, the business earned ($4.40) earnings per share. As a group, sell-side analysts anticipate that Bristol-Myers Squibb will post 6.74 EPS for the current fiscal year.

Analysts Set New Price Targets

Several analysts have commented on the stock. Cantor Fitzgerald reissued a "neutral" rating and issued a $55.00 target price on shares of Bristol-Myers Squibb in a research report on Tuesday, April 22nd. UBS Group decreased their price target on Bristol-Myers Squibb from $60.00 to $54.00 and set a "neutral" rating for the company in a research note on Friday, April 11th. Argus raised Bristol-Myers Squibb to a "hold" rating in a research note on Friday, April 25th. Wall Street Zen lowered shares of Bristol-Myers Squibb from a "strong-buy" rating to a "buy" rating in a research note on Friday. Finally, Piper Sandler began coverage on shares of Bristol-Myers Squibb in a report on Tuesday, April 22nd. They set an "overweight" rating and a $65.00 price target for the company. Two equities research analysts have rated the stock with a sell rating, thirteen have given a hold rating, six have issued a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, Bristol-Myers Squibb has an average rating of "Hold" and an average target price of $58.00.

Insider Buying and Selling at Bristol-Myers Squibb

In other Bristol-Myers Squibb news, EVP Samit Hirawat bought 4,250 shares of Bristol-Myers Squibb stock in a transaction on Friday, April 25th. The shares were purchased at an average cost of $47.58 per share, for a total transaction of $202,215.00. Following the completion of the acquisition, the executive vice president now owns 83,513 shares in the company, valued at approximately $3,973,548.54. The trade was a 5.36% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website. Corporate insiders own 0.09% of the company's stock.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.